Ronald Green

In March of 1992, I was diagnosed with prostate cancer. Tests showed metastasis to one lymph node in the pelvic region. Radiation therapy was precluded because I had undergone a previous radiation treatment to that region in 1986 when I was fighting a first cancer, a sarcoma, in the pelvic tissue.

Initially, radical surgery was attempted because a good response to treatment with the hormone Megace was expected. However, the operation was aborted because the surgeon estimated that the cancer had spread to the bladder. At that time, he recommended I switch to Lupron, which was meant to be a delay tactic only.

My daughter did research at the library and read about an alternative treatment using antineoplastons provided by Dr. Burzynski. I began antineoplaston treatment on December 7, 1992. I came off all other treatment in mid-January of 1993.

My PSA levels initially stayed below 2.0, but eventually started to increase. Whenever I increased the dosage of antineoplastons, including intravenous, my PSA level would decrease for a month and then begin to increase. I repeated this cycle several times. Because my health insurance would not cover any of the cost, however, I began to search for a conventional treatment that insurance would cover.

I consulted several doctors who agreed the cancer had decreased enough to allow me to either undergo radical surgery or cryoablation. Because impotence was assured with the radical because of the previous radiation, I opted for the cryosurgery, which provided a chance at maintaining potency.

I had a successful cryoablation in January 1995 and continued on antineoplastons until the end of May 1995. Because my PSA levels had been 0.0 for 4 months, I ceased all treatment. My PSA varied between 0.45 and 1.0 until June of 1998 and then began to increase gradually. With a PSA level of 2.1 in February of 1999, I underwent a biopsy. Cancer cells were found in the prostate that I had remaining. I had brachytherapy on March 11, 1999. My most recent PSA level was 0.3.

I was only frozen once with cryosurgery. Now the doctors recommend two freezes because only one most likely will not kill all the cancer cells. I will now continue to watch my PSA levels to evaluate the effects of the last treatment. As a sidelight, although I had lost potency with the cryosurgery, potency returned after 18 months. A downside is that I have become incontinent from four bladder resections required as a result of the formation of scar tissue from the cryosurgery and several problems from the hemorrhagic stroke attributed to the hormone treatment.

Since the sarcoma in 1986 and prostate cancer in 1992, I have undergone three major and four minor operations (two surgeries for the sarcoma and radiation, an aborted radical, hormone therapy, a cryoablation, antineoplastons, and now brachytherapy). I will always have adverse side effects from the radiation, cryosurgery, and hormones. However, I have had no adverse side effects from the antineoplastons or brachytherapy.

Dr. Burzynski and antineoplaston therapy took me from being a hopeless case to where I have had and continue to have other options. In fact, a cure is now possible. Antineoplastons should be available as one of the possible options for all people faced with cancer.

Ronald R. Green

May 1999